Welcome to our dedicated page for ROCKWELL MEDICAL SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKWELL MEDICAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKWELL MEDICAL's regulatory disclosures and financial reporting.
Rockwell Medical, Inc. (RMTI) furnished an updated corporate presentation under Regulation FD. The presentation, dated November 12, 2025, is provided as Exhibit 99.1 to a Form 8‑K.
The company states the information in this report, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act pursuant to General Instruction B.2. The exhibit list also includes Exhibit 104 for the cover page interactive data file.
Rockwell Medical (RMTI) reported a weaker quarter. Q3 2025 net sales were $15.9 million versus $28.3 million a year ago, driving gross profit of $2.3 million and an operating loss of $1.6 million. Net loss was $1.8 million, or $0.05 per share, compared with net income of $1.7 million last year.
For the first nine months, net sales were $50.9 million versus $76.8 million, with a net loss of $4.8 million. Cash, cash equivalents and available-for-sale investments totaled $23.7 million, and net working capital was $27.9 million; management believes funds are sufficient for at least the next twelve months.
DaVita extended its purchase agreement through December 31, 2025 but is transitioning to another supplier. Rockwell recognized non-refundable payments of $1.7 million year-to-date, including $0.4 million in Q3, and continues to supply DaVita. The company raised $8.0 million gross ($7.8 million net) via its ATM in Q3, with $13.1 million remaining available. Rockwell closed its Greer, South Carolina facility, recording $0.5 million in Q3 and $0.8 million year-to-date in closure costs. Term loan balance was $8.7 million, interest-only through 36 months, with all covenants in compliance. Shares outstanding were 39,405,301 as of September 30, 2025.
Rockwell Medical, Inc. (RMTI) furnished its quarterly results press release. The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and furnished it as Exhibit 99.1 to a Form 8-K.
Consistent with General Instruction B.2, the Item 2.02 information and Exhibit 99.1 are furnished, not filed, and are not incorporated by reference into other filings unless expressly stated. The report was signed by Chief Executive Officer Mark Strobeck.
Insider sale under a trading plan: Senior Vice President and Chief Operating Officer Heather Hunter reported a sale of 2,868 shares of Rockwell Medical, Inc. (RMTI) on 10/01/2025 at a price of $1.19 per share, leaving her with 135,391 shares beneficially owned after the transaction. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on 12/13/2024, which creates an affirmative defense for scheduled insider trades.
The Form 4 was signed by an attorney-in-fact on 10/08/2025 and includes a remark that the filing is late due to administrative delays obtaining EDGAR codes. No derivative transactions or other non‑derivative purchases were reported on this form.
Heather Hunter, Senior Vice President and Chief Operating Officer of Rockwell Medical, Inc. (RMTI), reported ownership of 138,259 shares of common stock and several option and restricted stock unit grants. The filing lists non-qualified stock options exercisable through 09/09/2032, 03/17/2033, 03/14/2034, and 05/20/2035 with exercise prices of $1.66, $1.37, $1.39, and $1.07, respectively. The report notes RSUs vesting in 2026 and 2027 and discloses the Form 3 was filed late for administrative reasons.
Insider sale under a 10b5-1 plan: Mark Strobeck, President and CEO and a director of Rockwell Medical, sold 6,926 shares of Rockwell Medical common stock on 10/01/2025 at a reported price of $1.19 per share.
After the transaction, the filing reports Mr. Strobeck beneficially owns 330,826 shares, held directly. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted May 30, 2024, and the filer offers to provide details of the number of shares and prices upon request.
Rockwell Medical, Inc. (RMTI) filing a Form 144 reports a proposed sale of 2,868 common shares through Raymond James & Associates on 10/01/2025 on NASDAQ with an aggregate market value of 3,321.00. The filing shows the securities were acquired by the seller through RSU vesting on 03/15/2024 (10,010 shares) and 03/14/2025 (8,666 shares). The filer sold 2,868 shares on 07/01/2025 for gross proceeds of 2,271.00. The notice includes the standard attestation that the seller does not possess undisclosed material adverse information.
Rockwell Medical, Inc. reported that its Board of Directors appointed Heather Hunter as Senior Vice President and Chief Operating Officer, effective immediately. She has been serving as the company’s Senior Vice President and Chief Corporate Affairs Officer since August 2022 and previously held senior communications and corporate affairs roles at Venatorx Pharmaceuticals, Safeguard Scientifics, and W.P. Carey.
Hunter’s existing employment agreement, dated August 31, 2022 and amended May 20, 2025, provides an annualized base salary of $323,574, a target bonus opportunity equal to 45% of base salary, eligibility for long-term incentive awards, and an initial time-based stock option to purchase up to 60,000 shares vesting over four years. The agreement includes severance and equity-vesting protections in cases of death, disability, certain terminations without cause or for good reason, and change of control, along with standard confidentiality, inventions assignment, non-interference, and non-competition obligations.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 2,149,471 shares of Rockwell Medical common stock, representing 6.29% of the class. The reporting persons state they exercise shared voting and dispositive power over these shares through Armistice Capital's role as investment manager of the Armistice Capital Master Fund, the direct holder. The Master Fund is identified as the record owner but disclaims beneficial ownership due to the investment management agreement. No sole voting or dispositive power is reported.
The disclosure clarifies ownership structure and control relationships: Armistice Capital acts as adviser and Steven Boyd, as managing member, is identified as having shared beneficial influence over the reported position.
Rockwell Medical, Inc. filed a Form S-8 registration statement to register an additional 5,000,000 shares of its common stock, par value $0.0001 per share, issuable under the Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan. This filing adds to prior Form S-8 registrations from 2018, 2020, 2022, and 2023 that are incorporated by reference, and is intended to provide more shares for equity-based compensation to directors, executives, and other eligible participants under the plan.